Although Shmelkov et al had showed that CD133 expression was not restricted to CSCs of colorectal cancer and CD133- subsets could also initiate tumors[54], This present results indicate that CD133, as detected with immunohistochemistry method, is significantly associated with worse 5-year OS rate and DSF rate in CRC patients. This evidence concerns the gene PROM1 and colorectal carcinoma.